Sarepta Therapeutics, Inc.
EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
Last updated:
Abstract:
Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 51 skipping are described.
Status:
Application
Type:
Utility
Filling date:
12 Jun 2019
Issue date:
11 Aug 2022